IPCA Laboratories and Aurobindo Pharma have both signed significant global licensing agreements with Bhami Research Lab (BRL) to develop monoclonal antibody therapies for oncology and inflammatory diseases. According to reports from CNBC TV18, BRL will receive defined milestone fees for technology transfer royalty and royalty on net sales upon commercialization of the products. IPCA Labs stock ended the previous session 1.5% lower at ₹1,589 per share, though it has gained 13.7% year-to-date. Aurobindo Pharma stock closed 0.3% up at ₹1,468 with a 23% year-to-date gain.
Aurobindo Pharma faces regulatory challenges as the US Food and Drug Administration issued 11 observations for the company's Eugia Unit III manufacturing facility in Telangana. As reported by CNBC TV18, the USFDA inspected the formulations manufacturing unit from January 27 to February 6, following which it issued the regulatory observations. An Official Action Indicated (OAI) classification indicates significant regulatory violations were found at the facility, with the agency recommending formal administrative or regulatory action. The stock ended the previous session 0.3% up at ₹1,468 despite the regulatory concerns.
Dr Reddy's Laboratories has achieved a significant milestone with the first-to-market launch of Bosutinib tablets 400mg, which represents Bosulif in the United States market. According to CNBC TV18, the company was the first to file for the oncology drug, with its market size estimated at $253.8 million in the 12 months ending April 2026. The stock ended the previous session 0.2% lower at ₹1,272.9 and has declined 4.8% in the past month, though it remains 1.6% higher year-to-date.
Krishna Institute of Medical Sciences (KIMS) has announced plans to raise ₹600 crore through the issuance of warrants to promoters. As reported by CNBC TV18, the board will issue 77.02 lakh warrants to the promoter group at ₹779 per warrant, with these warrants fully convertible into equity shares within 18 months. The company will convene an Extraordinary General Meeting on July 9 to seek shareholder approval for this proposed fund raise. KIMS shares ended 2.3% higher at ₹783 on Friday, with the stock up 27% year-to-date.
